Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

1(20%)

Results Posted

25%(1 trials)

Phase Distribution

Ph not_applicable

20%

Ph phase_2

20%

Ph phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(4)

Detailed Status

Completed4

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

N/A1 (33.3%)

Trials by Status

recruiting120%

completed480%

Recent Activity

1 active trials

Showing 5 of 5

completedphase_2

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

NCT02599480

completedphase_1

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

NCT04599634

recruiting

Cognitive Disorders in Hereditary Spastic Paraplegia Type 4

NCT06260982

completednot_applicable

Brown Adipose Tissue in ALS

NCT03150290

completed

Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)

NCT02394743

Clinical Trials (5)

Showing 5 of 5 trials

NCT02599480Phase 2

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

Completed

NCT04599634Phase 1

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Completed

NCT06260982

Cognitive Disorders in Hereditary Spastic Paraplegia Type 4

Recruiting

NCT03150290Not Applicable

Brown Adipose Tissue in ALS

Completed

NCT02394743

Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)

Completed

All 5 trials loaded

Drug Details

Intervention Type: DIAGNOSTIC TEST
Total Trials: 5